semaj83/ctmatch_classification huggingface dataset:
Patient description: A 53-year-old man presents with chronic HCV infection for the past 2 years. His past medical history is only significant for inguinal hernia surgery when he was 20 years old. He is on IFN (100 mg/week) plus RBV (400 mg/day) combination therapy for the past 9 months. Direct antiviral drugs were added to his treatment 6 months ago. His medical record shows previous positive HCV RNA tests as well as positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Hepatitis C Non-Alcoholic Fatty Liver Disease Subjects will be eligible for enrollment in this study if they meet the following Males or females; age at least 18 years at screening Abnormal ALT > 65 IU/L (ie, approximately 1.5 x upper limit of normal) Negative urine pregnancy test (for women of childbearing potential) documented within the 24-hour period prior to the first dose of silymarin. Females of childbearing potential must be using two reliable forms of effective contraception during the study (while on drug and during follow-up) Hepatitis C virus (HCV) patients Previous treatment with any interferon-based therapy without sustained virological response Serum HCV RNA above quantifiable level of detection by the assay, within 1 year of screening and after the end of therapy No antiviral therapy for at least 6 months prior to screening visit Nonalcoholic fatty liver disease (NAFLD) patients Liver biopsy compatible with NAFLD within 3 years of screening  Subjects with any of the following will not be eligible for participation Use of silymarin or other milk thistle preparations within 30 days of screening Use of other antioxidants such as vitamin E, vitamin C, glutathione, alpha-tocopherol, within 30 days of screening. A multivitamin at standard doses will be allowed Allergy/sensitivity to milk thistle or its preparations Use of silymarin or other antioxidants (as above) during the screening period Use of warfarin, metronidazole or chronic use of acetaminophen greater than two gram per day Previous liver biopsy that demonstrated presence of cirrhosis Previous liver biopsy that demonstrated greater than or equal to 15% steatosis or evidence of steatohepatitis for HCV cohort Positive test for anti-HIV or HBsAg within 3 years of screening Positive urine drug screen for drugs of abuse at screening
Patient description: A 53-year-old man presents with chronic HCV infection for the past 2 years. His past medical history is only significant for inguinal hernia surgery when he was 20 years old. He is on IFN (100 mg/week) plus RBV (400 mg/day) combination therapy for the past 9 months. Direct antiviral drugs were added to his treatment 6 months ago. His medical record shows previous positive HCV RNA tests as well as positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Chronic Hepatitis C Age ≥18 years Chronic hepatitis C infection (at least 6 months) evidenced by a positive enzyme immunoassay for anti-HCV-antibodies and a positive quantitative RT-PCR amplification of HCV RNA Chronic inflammation on liver biopsy compatible with a diagnosis of chronic viral hepatitis HCV genotype 4 Patients that have not previously received peginterferon  Patients unable to take oral medications Use of ribavirin within 30 days prior to enrollment Females who are either pregnant, breast-feeding or not using birth control and are sexually active Any investigational drug therapy within 30 days prior to enrollment other than through Romark study number RM01-3027 Patients with other causes of liver disease Transplant recipients receiving immune suppression therapy Patient co-infected with human immunodeficiency virus, hepatitis A virus, hepatitis B virus, or hepatitis D virus based on enzyme immunoassay Patients with decompensated cirrhosis, thrombocytopenia (platelet count <80,000), neutropenia, history of variceal bleeding, ascites, hepatic encephalopathy or CTP scores >6 Patients with history of alcoholism (unless abstinent for 2 years) or with an alcohol consumption of >20 grams per day Patients who are clinically unstable
Patient description: A 53-year-old man presents with chronic HCV infection for the past 2 years. His past medical history is only significant for inguinal hernia surgery when he was 20 years old. He is on IFN (100 mg/week) plus RBV (400 mg/day) combination therapy for the past 9 months. Direct antiviral drugs were added to his treatment 6 months ago. His medical record shows previous positive HCV RNA tests as well as positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Chronic Hepatitis C Age ≥ 18 years Chronic hepatitis C infection (at least 6 months) evidenced by a positive enzyme immunoassay for anti-HCV-antibodies and a positive quantitative RT-PCR amplification of HCV RNA Chronic inflammation on liver biopsy compatible with a diagnosis of chronic viral hepatitis  Patients unable to take oral medications Use of interferon alpha within 90 days or ribavirin within 30 days prior to enrollment Females of child bearing age who are either pregnant, breast-feeding or not using birth control and are sexually active Any investigational drug therapy within 30 days prior to enrollment Patients with other causes of liver disease Patients co-infected with hepatitis A virus, hepatitis B virus or hepatitis D virus based on enzyme immunoassay Patients with history of alcoholism or with an alcohol consumption of >40 grams per day Patients who are clinically unstable Patients with any concomitant condition that, in the opinion of the investigator would preclude evaluation of response or make it unlikely that the contemplated course of therapy and follow-up could be completed History of hypersensitivity or intolerance to nitazoxanide or any of the excipients comprising the nitazoxanide tablets
Patient description: A 53-year-old man presents with chronic HCV infection for the past 2 years. His past medical history is only significant for inguinal hernia surgery when he was 20 years old. He is on IFN (100 mg/week) plus RBV (400 mg/day) combination therapy for the past 9 months. Direct antiviral drugs were added to his treatment 6 months ago. His medical record shows previous positive HCV RNA tests as well as positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Chronic Hepatitis C Age ≥18 years Chronic hepatitis C infection (at least 6 months) evidenced by a positive enzyme immunoassay for anti-HCV-antibodies and a positive quantitative RT-PCR amplification of HCV RNA Chronic inflammation on liver biopsy compatible with a diagnosis of chronic viral hepatitis HCV genotype 4  Patients who have previously failed to respond to ≥12 weeks of peginterferon-ribavirin combination therapy Females who are either pregnant, breast-feeding or not using birth control and are sexually active Males whose female partners are pregnant Patients with other causes of liver disease (i.e., autoimmune hepatitis, decompensated liver disease) Patients co-infected with hepatitis A virus, hepatitis B virus or hepatitis D virus Patients with a history of alcoholism or with an alcohol consumption of >40 grams per day Patients with hemoglobinopathies (i.e., thalassemia major, sickle-cell anemia) Patients with any concomitant condition that, in the opinion of the investigator, would preclude evaluation of response or make it unlikely that the contemplated course of therapy and follow-up could be completed History of hypersensitivity or intolerance to any of the excipients comprising the nitazoxanide tablets, peginterferon alfa-2a injectionable solution or ribavirin tablets
Patient description: A 53-year-old man presents with chronic HCV infection for the past 2 years. His past medical history is only significant for inguinal hernia surgery when he was 20 years old. He is on IFN (100 mg/week) plus RBV (400 mg/day) combination therapy for the past 9 months. Direct antiviral drugs were added to his treatment 6 months ago. His medical record shows previous positive HCV RNA tests as well as positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.

Clinical trial eligibility criteria: eligible ages (years): 14.0-999.0,  Unspecified Adult Solid Tumor, Protocol Specific Histologically or cytologically confirmed malignant solid tumor Refractory disease for which curative or palliative measures have failed or for which there is no known superior treatment No colorectal cancer or melanoma Measurable OR nonmeasurable disease Normotensive (blood pressure [BP] ≤ 140/90 mm Hg) meeting 1 of the following No more than 2 attempted measurement sessions for which the documented mean systolic BP is ≤ 140 mm Hg and the diastolic BP is ≤ 90 mm Hg At least 30 attempted measurement sessions for which the documented mean systolic BP is ≤ 135 mm HG and the diastolic BP is ≤ 85 mm Hg Brain metastases allowed provided the following are met Stable neurologic status for ≥ 2 weeks after completion of definitive local therapy (surgery or radiotherapy) No neurologic dysfunction that would confound the evaluation of neurologic and other adverse events
Patient description: A 53-year-old man presents with chronic HCV infection for the past 2 years. His past medical history is only significant for inguinal hernia surgery when he was 20 years old. He is on IFN (100 mg/week) plus RBV (400 mg/day) combination therapy for the past 9 months. Direct antiviral drugs were added to his treatment 6 months ago. His medical record shows previous positive HCV RNA tests as well as positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Venous Thrombosis Pulmonary Embolism Age 19-65 years 2. BMI 35-65 Kg/m2 3. Pregnancy test Negative on day of study 4. Past DVT/PE/MI These patients will not be excluded providing they are not on current therapy with anticoagulants, aspirin, or anti-platelet agents. 1. BP ≥ 160/90 2. Temperature > 37.5 0C (99.5 0F) 3. Nursing mothers if nursing 4. Pregnancy test Positive on day of study 5. Medications Anticoagulants, anti-platelet agents, aspirin, NSAIDs within a month of the study Past medical history 1. cerebrovascular accident (including TIA within 6 months of the study) 2. Diabetic retinopathy proven by fundoscopy 3. History of inherited thrombotic/hypercoagulable defect 4. Active peptic ulcer disease diagnosed by upper endoscopy 5. Known bleeding disorder, thrombophilia 6. History of heparin induced thrombocytopenia 7. History of bacterial endocarditis 8. Known hypersensitivity to fondaparinux 9. Ulcerative colitis 10. History of GI bleeding 11. History of hematuria 12. Recent surgery (last 3 months) 13. Recent trauma (last 3 months) Laboratory values 1. Platelet count ≤ 100,000 mm3 2. Hemoglobin < 12 g/dL (women), or < 14 g/dL (men) 3. Prothrombin time > 13 sec 4. PTT > 35 sec 5. ALT 3xULN and bilirubin 1.5xULN (>35% direct); or ALT 5xULN; or ALT 3xULN if associated with the appearance or worsening of hepatitis symptoms or rash 6. Estimated urinary creatinine clearance ≤ 50 ml/min 7. Hematuria on urine dipstick
Patient description: A 53-year-old man presents with chronic HCV infection for the past 2 years. His past medical history is only significant for inguinal hernia surgery when he was 20 years old. He is on IFN (100 mg/week) plus RBV (400 mg/day) combination therapy for the past 9 months. Direct antiviral drugs were added to his treatment 6 months ago. His medical record shows previous positive HCV RNA tests as well as positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  HIV Infections Hepatitis C Subject is >18 years old Subject has given written informed consent Subject has a confirmed diagnosis of HIV and HCV infection Subject is naive for HCV-infection treatment Subject has chronic hepatitis and/or subject has compensated cirrhosis (Child class A) Subject has a CD4+ count of > 350 cell/mmc Subject is HIV-RNA negative during the previous six month Subject is on stable HAART including r/LPV for > 6 months Subject has genotype available at baseline and no mutations associated with resistance to PI or no virologic failure on PI treatment, defined as a confirmed HIV-RNA level>50 cp/mL after 24 weeks, > 50 cp/ml after 48 weeks, or a repeated HIV RNA level > 50 cp/mL after prior suppression of viremia to< 50 cps/mL Free of any clinically significant disease (other than HIV and HCV) that would interfere with study evaluations  Subject is HbsAg positive Subject has cirrhosis score Child-Pugh B/C No previous hepatic decompensation Subject has HIV-related thrombocytopenia (Platelets count < 50.000/mmc) Subject has neutrophils count < 1500/mmc Subject has Hb value < 11 g/dL Subject has creatinine value > 1.5 mg/dL Subject is pregnant or wishes to become so Subject has any cause of liver disease other than chronic hepatitis C, status of liver decompensation or any other condition consistent with decompensated liver disease (bleeding from esophageal varices, signs of current bleeding, significant ascites, hepatic encephalopathy) Subject is alcohol abuser (> 30 gr/die)
Patient description: A 53-year-old man presents with chronic HCV infection for the past 2 years. His past medical history is only significant for inguinal hernia surgery when he was 20 years old. He is on IFN (100 mg/week) plus RBV (400 mg/day) combination therapy for the past 9 months. Direct antiviral drugs were added to his treatment 6 months ago. His medical record shows previous positive HCV RNA tests as well as positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Hepatitis C Hepatitis C  HIV positivity
Patient description: A 53-year-old man presents with chronic HCV infection for the past 2 years. His past medical history is only significant for inguinal hernia surgery when he was 20 years old. He is on IFN (100 mg/week) plus RBV (400 mg/day) combination therapy for the past 9 months. Direct antiviral drugs were added to his treatment 6 months ago. His medical record shows previous positive HCV RNA tests as well as positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Chronic Hepatitis C Hepatic Fibrosis Age older than 18 years HCV RNA and anti-HCV positivity for more than 6 months consecutive normal ALT values (< 40 IU/L for men and < 34 IU/L for women)at 3 months apart over a period of 12 months  HBV and HCV co-infection HBV and HIV co-infection History of heavy alcohol use (> 50 gram/day) Autoimmune liver diseases Metabolic liver diseases Presence of hepatocellular carcinoma Bleeding tendency Decline liver biopsies
Patient description: A 53-year-old man presents with chronic HCV infection for the past 2 years. His past medical history is only significant for inguinal hernia surgery when he was 20 years old. He is on IFN (100 mg/week) plus RBV (400 mg/day) combination therapy for the past 9 months. Direct antiviral drugs were added to his treatment 6 months ago. His medical record shows previous positive HCV RNA tests as well as positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Chronic Hepatitis C Hepatic Fibrosis Cirrhosis Age older than 18 years Positive anti-HCV and HCV RNA for more than 6 months Alanine aminotransferase level more than twice the upper limit of normal (ULN)  HBV and HCV co-infection HIV and HCV co-infection Heavy alcohol use (> 50 gram/day) Autoimmune liver diseases Metabolic liver diseases Presence of hepatocellular carcinoma
Patient description: A 53-year-old man presents with chronic HCV infection for the past 2 years. His past medical history is only significant for inguinal hernia surgery when he was 20 years old. He is on IFN (100 mg/week) plus RBV (400 mg/day) combination therapy for the past 9 months. Direct antiviral drugs were added to his treatment 6 months ago. His medical record shows previous positive HCV RNA tests as well as positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.

Clinical trial eligibility criteria: eligible ages (years): 18.0-50.0,  Hepatitis C Chronic Disease Treatment Adult males and non-pregnant females (more than 18 and less than equal to 50 years of age) Treatment naïve patients Serological evidence of hepatitis C infection by an anti-HCV antibody test HCV PCR positive Genotype 3 Absence of cirrhosis on liver biopsy Absence of alcohol or drug abuse  Patients who do not consent to be included in the study Pregnant or breast feeding females Patients with a hemoglobin of <10g/dl, ANC <1500c/mm, and a platelet count <90000c/mm Genotype non 3 HCV PCR positive at the end of 4 weeks of treatment Presence of cirrhosis on liver biopsy Decompensated liver disease History or other evidence of a medical condition associated with chronic liver disease other than CHC (e.g., hemochromatosis, autoimmune hepatitis, metabolic liver disease, alcoholic liver disease, toxin exposure) History of having received IFN, PEG-IFN, RBV therapy previously History of systemic antiviral therapy or investigational drug 3 months prior to the first dose of study treatment
Patient description: A 53-year-old man presents with chronic HCV infection for the past 2 years. His past medical history is only significant for inguinal hernia surgery when he was 20 years old. He is on IFN (100 mg/week) plus RBV (400 mg/day) combination therapy for the past 9 months. Direct antiviral drugs were added to his treatment 6 months ago. His medical record shows previous positive HCV RNA tests as well as positive enzyme immunoassay for anti-HCV-antibodies. The recent biopsy was negative for hepatocellular carcinoma and was only remarkable for chronic inflammation compatible with a chronic viral hepatitis. There is no evidence of alcoholic liver disease, bleeding from esophageal varices, hemochromatosis, autoimmune hepatitis or metabolic liver disease. He is an alert male with no acute distress. His BP: 130/75, HR: 90/min and BMI: 27. His abdomen is soft with no ascites or tenderness. The lower extremities are normal with no edema.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Hepatitis C HCV RNA: Positive Biopsy approved in genotype 1 Age older than 18 yrs  ongoing pregnancy or breast feeding Hx of hemochromatosis Hx of metabolic liver dis Hx of HCC Hx of autoimmune hepatitis Hx of alcoholic liver dis Hx of bleeding from esophageal varices ongoing systemic anti-viral or anti-neoplasmic treatment Hx of treatment with an anti-depressant medication at therapeutic doses for at least 3 months at any pervious time Hx of treatment with an tranquilizer at therapeutic doses for psychosis for at least 3 months at any pervious time